Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

BWAY - BrainsWay Ltd. Latest News | Finranks

Home

BWAY

(BWAY)

NGM – Real Time Price. Currency in USD

12.87

-0.62 (-4.60%)

At close: Mar 27, 2026, 4:00 PM EDT

12.59

-0.28 (-2.18%)

After-hours: Mar 27, 2026, 7:30 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BrainsWay's investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care

Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

Landmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70% World's only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70%

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care

BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent news issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magnetic stimulation (TMS) for contracted providers whose patients have coverage under Evernorth and Cigna Healthcare® plans. The Evernorth press release stated that the change will be effective on March 6, 2026.